AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS

MEDICAL GUIDELINES FOR CLINICAL PRACTICE

FOR THE EVALUATION AND TREATMENT OF
HYPERTHYROIDISM AND HYPOTHYROIDISM
AACE Thyroid Task Force

Chairman
H. Jack Baskin, MD, MACE

Committee Members
Rhoda H. Cobin, MD, FACE
Daniel S. Duick, MD, FACE
Hossein Gharib, MD, FACE
Richard B. Guttler, MD, FACE
Michael M. Kaplan, MD, FACE
Robert L. Segal, MD, FACE

Reviewers
Jeffrey R. Garber, MD, FACE
Carlos R. Hamilton, Jr., MD, FACE
Yehuda Handelsman, MD, FACP, FACE
Richard Hellman, MD, FACP, FACE
John S. Kukora, MD, FACS, FACE
Philip Levy, MD, FACE
Pasquale J. Palumbo, MD, MACE
Steven M. Petak, MD, JD, FACE
Herbert I. Rettinger, MD, MBA, FACE
Helena W. Rodbard, MD, FACE
F. John Service, MD, PhD, FACE, FACP, FRCPC
Talla P. Shankar, MD, FACE
Sheldon S. Stoffer, MD, FACE
John B. Tourtelot, MD, FACE, CDR, USN

2006 AMENDED VERSION

This amended version reflects a clarification to specify pertechnetate as the
compound attached to 99mTc.

ENDOCRINE PRACTICE Vol 8 No. 6 November/December 2002 457

AACE Guidelines
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS
MEDICAL GUIDELINES FOR CLINICAL PRACTICE
FOR THE EVALUATION AND TREATMENT OF
HYPERTHYROIDISM AND HYPOTHYROIDISM
ABSTRACT
These clinical practice guidelines summarize the rec-
ommendations of the American Association of Clinical
Endocrinologists for the diagnostic evaluation of hyper-
thyroidism and hypothyroidism and for treatment strate-
gies in patients with these disorders. The sensitive thyroid-
stimulating hormone (TSH or thyrotropin) assay has
become the single best screening test for hyperthyroidism
and hypothyroidism, and in most outpatient clinical situa-
tions, the serum TSH is the most sensitive test for detect-
ing mild thyroid hormone excess or deficiency.
Therapeutic options for patients with Graves’ disease
include thyroidectomy (rarely used now in the United
States), antithyroid drugs (frequently associated with
relapses), and radioactive iodine (currently the treatment
of choice). In clinical hypothyroidism, the standard treat-
ment is levothyroxine replacement, which must be tailored
to the individual patient. Awareness of subclinical thyroid
disease, which often remains undiagnosed, is emphasized,
as is a system of care that incorporates regular follow-up
surveillance by one physician as well as education and
involvement of the patient. (Endocr Pract. 2002;8:457-
469)
Abbreviations:
AACE = American Association of Clinical
Endocrinologists; RIA = radioimmunoassay; T3 = tri-
iodothyronine; T4 = thyroxine; TRAb = thyrotropin
receptor antibodies; TSH = thyroid-stimulating hormone
(thyrotropin); TSI = thyroid-stimulating immunoglobu-
lins
MISSION STATEMENTS
Guidelines Mission Statement
The purpose of these guidelines is to present a frame-
work for the diagnosis, treatment, and follow-up of
patients with hyperthyroidism and hypothyroidism. These
thyroid guidelines address the difficulties involved in
diagnosing thyroid disease and offer a system of care that
should improve outcomes and reduce costs. The American
Association of Clinical Endocrinologists (AACE) advo-
cates a continuum of care by one physician with expertise
in the diagnosis and treatment of thyroid disease and
458 ENDOCRINE PRACTICE Vol 8 No. 6 November/December 2002
follow-up conducted at regular intervals throughout the
course of the patient’s disease.
Public Service Mission Statement
Since the original AACE Thyroid Guidelines were
published in 1995 (1), the sensitive thyroid-stimulating
hormone (TSH or thyrotropin) assay has become the pri-
mary test to diagnose and treat thyroid disease, and sub-
clinical thyroid disease has been more precisely defined
and diagnosed. Subclinical hyperthyroidism has been
shown to affect the health of untreated patients adversely,
and subclinical hypothyroidism may also have important
health consequences.
Patients with subclinical hyperthyroidism are often
those who have received excessive amounts of thyroid
hormone, which may result in an accelerated rate of bone
loss—a frequent problem in the postmenopausal popula-
tion. In addition, cardiac hypertrophy and atrial fibrillation
are possible consequences of subclinical hyperthyroidism.
The cardiac and bone problems in these patients can be
prevented by the timely identification and correction of
thyroid overreplacement.
Subclinical hypothyroidism is also an important con-
dition, affecting up to 20% of persons beyond 60 years of
age. Clinical endocrinologists agree that most patients
with subclinical hypothyroidism require therapy.
Although patients with this disorder can be asymptomatic,
some patients have subtle findings, including alterations in
lipid metabolism, cardiac, gastrointestinal, neuropsychi-
atric, and reproductive abnormalities, and an increased
likelihood of developing a goiter. For increased recogni-
tion of subclinical hypothyroidism, physician education
and patient awareness are necessary.
HYPERTHYROIDISM
Hyperthyroidism is the consequence of excessive thy-
roid hormone action. The causes of hyperthyroidism
include the following:
• Toxic diffuse goiter (Graves’ disease)
• Toxic adenoma
• Toxic multinodular goiter (Plummer’s disease)
• Painful subacute thyroiditis
• Silent thyroiditis, including lymphocytic and post-
partum variations
 AACE Thyroid Guidelines, Endocr Pract. 2002;8(No. 6) 459
• Iodine-induced hyperthyroidism (for example, related
to amiodarone therapy)
• Excessive pituitary TSH or trophoblastic disease
• Excessive ingestion of thyroid hormone
Clinical Features
The signs and symptoms of hyperthyroidism are
attributable to the effects of excess thyroid hormone in the
circulation. The severity of signs and symptoms may be
related to the duration of the illness, the magnitude of the
hormone excess, and the age of the patient.
The following list illustrates the spectrum of possible
signs and symptoms associated with the various causes of
hyperthyroidism:
• Nervousness and irritability
• Palpitations and tachycardia
• Heat intolerance or increased sweating
• Tremor
• Weight loss or gain
• Alterations in appetite
• Frequent bowel movements or diarrhea
• Dependent lower-extremity edema
• Sudden paralysis
• Exertional intolerance and dyspnea
• Menstrual disturbance (decreased flow)
• Impaired fertility
• Mental disturbances
• Sleep disturbances (including insomnia)
• Changes in vision, photophobia, eye irritation, diplo-
pia, or exophthalmos
• Fatigue and muscle weakness
• Thyroid enlargement (depending on cause)
• Pretibial myxedema (in patients with Graves’ disease)
A patient with hyperthyroidism need not have all
these symptoms (2-5).
Diagnosis
A comprehensive history should be elicited, and a
thorough physical examination should be performed,
including the following:
• Weight and blood pressure
• Pulse rate and cardiac rhythm
• Thyroid palpation and auscultation (to determine thy-
roid size, nodularity, and vascularity)
• Neuromuscular examination
• Eye examination (to detect evidence of exophthalmos
or ophthalmopathy)
• Dermatologic examination
• Cardiovascular examination
• Lymphatic examination (nodes and spleen)
Laboratory Evaluation
The development of sensitive TSH assays has consid-
erably facilitated the diagnosis of hyperthyroidism. The
sensitive TSH test refers to a TSH assay with a functional
sensitivity of 0.02 or less. Hyperthyroidism of any cause
(except excess TSH production) results in a lower-than-
normal TSH level (suppressed TSH). The sensitive TSH
assay is the single best screening test for hyperthyroidism,
and in most outpatient clinical situations, the serum TSH
is the most sensitive test for detecting mild (subclinical)
thyroid hormone excess or deficiency.
In patients with unstable thyroid states, such as those
recently treated for hyperthyroidism or those who have
been receiving excess thyroid hormone replacement,
serum thyroxine (T4) measurement more accurately indi-
cates the thyroid status than does serum TSH. Patients
with chronic or recent severe hyperthyroidism or hypothy-
roidism will benefit from having both TSH and T4 moni-
tored for 1 year until their condition becomes stable.
Elderly patients or those patients suspected of being non-
compliant also should have both TSH and T4 measure-
ments monitored.
Other laboratory and isotope tests may include the
following:
• T4 or free T4
• Triiodothyronine (T3) radioimmunoassay (RIA) or free
T3
Abnormal results of T4 or T3 measurements are often
due to binding protein abnormalities rather than abnor-
mal thyroid function. Therefore, total T4 or T3 must be
determined in conjunction with some measure of their
thyroid hormone binding such as T3 resin uptake or
assay of thyroid-binding globulin to yield a “free thy-
roid hormone estimate.” Commercial laboratories often
call these methods free T4 or free T3 even though they
do not measure free hormone directly.
• Thyroid autoantibodies, including TSH receptor anti-
bodies (TRAb) or thyroid-stimulating immunoglobu-
lins (TSI)
These studies are not routinely necessary but may be
helpful in selected cases, such as in patients with hyper-
thyroidism during pregnancy.
• Radioactive iodine uptake
• Thyroid scan—with either 123I (preferably) or 99mTc
pertechnetate
Such a scan is not a thyroid function test but is done to
help determine the cause of the hyperthyroidism. The
scan may also be useful in assessing the functional sta-
tus of any palpable thyroid irregularities or nodules
associated with a toxic goiter (5).
Reverse T3 testing is seldom, if ever, helpful in
clinical practice.
Differential Diagnosis
The diagnosis of overt Graves’ disease with ophthal-
mopathy is usually obvious. In elderly persons, however,
Graves’ disease may be more difficult to diagnose and
may manifest only with cardiac findings or weight loss
(apathetic or masked thyrotoxicosis). Some patients may
have a normal-size thyroid gland. The free thyroid hor-
mone (T4 and T3) estimates are usually high, although
some patients may have increased values only for free T3
460 AACE Thyroid Guidelines, Endocr Pract. 2002;8(No. 6)
estimate (T3 toxicosis). In Graves’ disease, the TSH level
measured with use of a sensitive assay is always
suppressed, and the thyroid scan shows diffuse isotope
uptake and sometimes a pyramidal lobe.
A toxic adenoma (“hot nodule”) is associated with a
low TSH level, with or without a high free T4 or T3 esti-
mate. The thyroid scan reveals a functioning nodule and
suppression of the extranodular thyroid tissue. Toxic
multinodular goiter has the same characteristics and simi-
lar laboratory findings as those associated with a toxic
nodule, but the thyroid gland is variably enlarged and
composed of multiple nodules. In both cases, radioactive
iodine uptake is usually increased but may be in the nor-
mal range.
A low radioiodine uptake in conjunction with poor
thyroid gland imaging on the thyroid scan characterizes
subacute thyroiditis, silent thyroiditis, iodine-induced
hyperthyroidism, and factitious thyroxine-induced hyper-
thyroidism. All these conditions are associated with
variably increased T4 and T3 levels on RIA during the
hyperthyroid phase.
Classic subacute thyroiditis is usually painful, some-
times causes fever, and is self-limited. The hyperthy-
roidism is due to the release of stored thyroid hormone
from the inflamed gland. Frequently, the early hyperthy-
roid phase leads to a hypothyroid phase during a 2- or 3-
month period, before resolution. Silent thyroiditis (pain-
less), thought to be an autoimmune disorder, has a similar
course; it is particularly common in postpartum women.
Iodine-induced hyperthyroidism occurs most often in the
older population and is typically seen in the setting of a
preexisting nontoxic nodular goiter. The iodine load, from
orally administered medications or supplements or from
intravenously administered contrast agents, induces the
hyperthyroidism, which does not readily resolve and may
necessitate specific treatment. Factitious thyrotoxicosis
produces a similar clinical picture; if suspected, it can be
confirmed by finding a very low or absent thyroglobulin
level (the thyroglobulin level is very high in all types of
thyroiditis).
Not all high values for T4 and T3 on RIA, and not all
suppressed TSH levels, are associated with hyperthy-
roidism. Estrogen administration or pregnancy raises the
thyroxine-binding globulin level and results in high total
T4 and T3 levels on RIA but normal free T4 and T3 esti-
mates and a normal result on sensitive TSH assay.
Euthyroid hyperthyroxinemia may also be attributable to
other abnormal binding proteins, including albumin and
prealbumin. Similarly, thyroid hormone resistance states
can cause increased serum T4 levels without hyperthy-
roidism. Administration of corticosteroids, severe illness,
and pituitary dysfunction can be associated with a sup-
pressed TSH level in the absence of hyperthyroidism.
Treatment and Management
Three types of therapy are available for Graves’ dis-
ease: (1) surgical intervention, (2) antithyroid drugs, and
(3) radioactive iodine.
Surgical Intervention
Although thyroidectomy for Graves’ disease was fre-
quently used in the past, it is now uncommonly performed
in the United States unless coexistent thyroid cancer is
suspected. Pregnant patients with hyperthyroidism who
are intolerant of antithyroid drugs or nonpregnant patients
desiring definitive therapy but who refuse radioactive
iodine treatment are candidates for surgical intervention.
Some physicians prefer surgical treatment of pediatric
patients with Graves’ disease or patients with very large or
nodular goiters. Potential complications associated with
surgical management of Graves’ disease include hypo-
parathyroidism and vocal cord paralysis in a small propor-
tion of patients. Surgeons trained and experienced in thy-
roid surgical procedures should perform this operation
(2,3,5).
Antithyroid Drugs
Antithyroid drugs, methimazole and propylthiouracil,
have been used since the 1940s and are prescribed in an
attempt to achieve a remission. The remission rates are
variable, and relapses are frequent. The patients in whom
remission is most likely to be achieved are those with mild
hyperthyroidism and small goiters. Antithyroid drug treat-
ment is not without the risk of adverse reactions, including
minor rashes and, in rare instances, agranulocytosis and
hepatitis. The success of this therapy depends on a high
degree of patient adherence to recommendations. Hyper-
thyroidism during pregnancy is one clear indication for
antithyroid drug treatment. Elderly or cardiac patients may
require “pretreatment” with antithyroid drugs, before
radioiodine therapy. Moreover, some endocrinologists
prefer antithyroid drug therapy in childhood Graves’ dis-
ease. Treatment of Graves’ disease with antithyroid drugs
alone is an alternative therapeutic strategy but is used in
only a minority of patients in the United States (2,3,6,7).
Radioactive Iodine
In the United States, radioactive iodine is currently
the treatment of choice for Graves’ disease. Many clinical
endocrinologists prefer an ablative dose of radioactive
iodine, but some prefer use of a smaller dose in an attempt
to render the patient euthyroid. Ablative therapy with
radioactive iodine yields quicker resolution of the hyper-
thyroidism than does small-dose therapy and thereby min-
imizes potential hyperthyroid-related morbidity.
Radioactive iodine therapy is safe, but most treated
patients become hypothyroid and require lifelong thyroid
replacement therapy. Some clinical endocrinologists are
hesitant to use radioactive iodine to treat patients of child-
bearing age, but no evidence has suggested that such ther-
apy has any adverse effects. Specifically, studies have
found no effect on fertility, no increased incidence of con-
genital malformations, and no increased risk of cancer in
patients treated with radioactive iodine or in their off-
spring. Elderly or cardiac patients with Graves’ disease
may require antithyroid drug therapy before treatment
with radioactive iodine, to deplete the thyroid gland of
 AACE Thyroid Guidelines, Endocr Pract. 2002;8(No. 6) 461
stored hormone and reduce the risk of excessive posttreat-
ment hyperthyroidism as a result of 131I-induced thyroid-
itis. Use of radioactive iodine is contraindicated during
pregnancy because it may ablate the thyroid in the fetus.
Before radioactive iodine treatment, a negative pregnancy
test should be obtained in all women of childbearing age,
and pregnancy should be postponed after such therapy. A
waiting period of 6 months is frequently advised. Further-
more, radioactive iodine should not be given to women
who are breast-feeding because it appears in the breast
milk. The use of radioactive iodine in patients younger
than 20 years has become commonplace.
After administration of a dose of radioactive iodine,
thyroid replacement therapy should be carefully initiated
during the time the patient’s thyroid function passes
through the normal range into the hypothyroid range. The
final thyroid replacement dose must be individualized.
This approach promptly resolves the hyperthyroidism with
a minimum of hypothyroid morbidity (2,3,6,7).
System of Care
Once the diagnosis of Graves’ disease with hyperthy-
roidism has been established, the patient should be given a
complete explanation of the illness and options for treat-
ment. The goal is to involve the patient as a partner in the
medical decision-making process and care, rather than
have the endocrinologist dictate the choice of therapy.
Patients who elect to receive radioactive iodine
should be given an explanation of the treatment, and a
consent form for such therapy should be signed (see exam-
ple in Appendix A). After receiving radioactive iodine,
patients should be given an instruction sheet that itemizes
appropriate precautions and explains follow-up manage-
ment (see example in Appendix B).
The radioactive iodine uptake should be assessed
before treatment to ensure adequate uptake at the time of
therapy, to rule out the presence of a variant of thyroiditis
or iodine contamination, and to help determine the dose of
radioactive iodine. A thyroid scan is also useful in distin-
guishing toxic nodular goiter and toxic adenoma from
Graves’ disease. Typically, toxic nodular goiter is more
resistant to radioactive iodine and frequently necessitates
use of a larger dose.
β-Adrenergic antagonists provide symptomatic relief
and can be administered before radioactive iodine is given.
Because patients with hyperthyroidism may be relatively
resistant to the effects of β-adrenergic blocking agents,
larger and more frequent doses may be necessary. The
dose of these drugs can be tapered and discontinued once
the patient no longer has hyperthyroidism. In addition, in
severe thyrotoxic states, adjuvant treatment can include
organic or inorganic iodides and antithyroid drugs after
radioactive iodine therapy.
After treatment with radioactive iodine, patients
should have follow-up examinations at frequent intervals
(varying from 4 to 6 weeks, but individualized for each
case) until they are euthyroid and their condition is stable.
Most patients will require full thyroid hormone replace-
ment therapy. Patients usually become hypothyroid within
3 months and could begin receiving partial replacement
doses of levothyroxine approximately 2 months after
receiving radioactive iodine. This schedule is determined
by laboratory testing and clinical evaluation. At this time,
the patient’s thyroid status is quickly changing from
euthyroid to hypothyroid, and the TSH level may not be a
good indicator of function because it fails to increase
quickly. From 2 weeks to several months may elapse
before TSH responsiveness is recovered, and free thyroid
hormone estimate tests are more accurate than TSH values
during this interval.
When the condition of patients has stabilized, the
frequency of visits and reevaluations can be extended. A
common schedule for follow-up consultations is at 3
months, at 6 months, and then annually, but this can be
modified on the basis of the physician’s judgment (2,3,6).
Hyperthyroidism During Pregnancy
Hyperthyroidism during pregnancy presents special
concerns and is best managed collaboratively by an obste-
trician and a clinical endocrinologist. Use of radioactive
iodine is contraindicated during pregnancy because it
crosses the placenta. Antithyroid drugs are the treatment
of choice for hyperthyroidism during pregnancy, and
propylthiouracil is clearly preferred over methimazole.
Antithyroid drugs also cross the placenta, and overtreat-
ment with them may adversely affect the fetus. Therefore,
the lowest possible dose of antithyroid drug should be
used to maintain the mother’s thyroid function at the upper
limit of normal. Because pregnancy itself has an ameliora-
tive effect on Graves’ disease, the dose of antithyroid drug
required usually decreases as the pregnancy progresses.
Often the antithyroid drug can be discontinued before
delivery. If surgical treatment does become necessary, it is
best done during the second trimester of pregnancy.
The patient’s active participation in treatment is criti-
cal to the successful outcome of pregnancy in the presence
of Graves’ disease. Of importance, the patient must under-
stand the risk of the disease, the pathophysiologic factors,
and the mechanisms involved in therapy. Patient education
will enhance adherence to recommended therapy as well
as awareness of changes that may necessitate treatment
alterations. With this background, the patient should
become more aware of the problems that might occur and
should alert her endocrinologist.
The patient should also be informed about changes
that may occur in her health or her baby’s health during
the postpartum period. She should be advised to inform
the pediatrician of her thyroid disease and of the possibil-
ity that neonatal hyperthyroidism or hypothyroidism
might develop in the baby. The infant’s thyroid function
must be tested at birth.
The patient should also be aware that postpartum
recurrence of the hyperthyroidism is likely. This finding
can be related to the Graves’ disease or postpartum thy-
roiditis. If overt hyperthyroidism due to Graves’ disease
develops after delivery, the patient may be offered the
alternative of resuming antithyroid drug therapy or receiv-
ing radioactive iodine. Radioactive iodine therapy is
462 AACE Thyroid Guidelines, Endocr Pract. 2002;8(No. 6)
contraindicated if the patient is breast-feeding or, of
course, is pregnant again. Postpartum follow-up with
appropriate assessment by a clinical endocrinologist
should be continued until the patient is in a stable euthy-
roid state.
Euthyroid pregnant patients treated for Graves’ dis-
ease before the pregnancy may still have stimulating
thyroid autoantibodies in the circulation, which can cross
the placenta. Measurement of maternal TSI (TRAb) may
be useful for assessment of potential fetal risk; on the basis
of clinical judgment, the endocrinologist can have this
study done (2,3,7).
Graves’ Ophthalmopathy
Exophthalmos and other eye signs are the hallmark of
Graves’ disease and may occasionally be seen in the
absence of hyperthyroidism. Severe Graves’ ophthal-
mopathy occurs in a minority of patients with Graves’
diathesis who are clinically euthyroid. The presence of
ophthalmopathy necessitates a thorough thyroid evalua-
tion. Orbital ultrasonography, computed tomography
(without a contrast agent), or magnetic resonance imaging
may be necessary, particularly in cases of unilateral
exophthalmos. The finding of characteristic extraocular
muscle swelling helps exclude the presence of a retro-
orbital tumor. Serial exophthalmometry can document
progression of the exophthalmos; such measurements are
easily obtained during office visits. The rationale for local
mechanical therapies—such as sunglasses, artificial tears,
elevation of the head of the bed, bedtime diuretics, and use
of eye protectors during sleep—should be explained to the
patient in an effort to enhance adherence to recommenda-
tions. More aggressive treatment with corticosteroids,
retro-orbital irradiation, or surgical intervention can be
considered for progressive and severe ophthalmopathy.
Consultation with an ophthalmologist experienced in the
treatment of orbital disease is recommended in the man-
agement of such cases.
The question of a deleterious effect of 131I therapy on
ophthalmopathy in some patients has been raised by some,
but not all, studies. The only two randomized studies sug-
gest that, in patients with Graves’ disease, thyroid-associ-
ated ophthalmopathy is slightly more likely to develop or
worsen if the hyperthyroidism is treated with 131I rather
than thyroidectomy or antithyroid drugs (8,9). Both of
these studies, however, have been criticized (10,11).
Investigators generally accept that most patients do not
have progression of their ophthalmopathy after radioactive
iodine therapy. Cigarette smoking, posttherapy hypothy-
roidism, and the duration and severity of the hyperthy-
roidism are other possible risk factors for the progression
of the ophthalmopathy. In patients with established oph-
thalmopathy, a course of corticosteroid therapy begun at
the same time as administration of 131I decreases the pos-
sibility of worsening the ophthalmopathy (12). The poten-
tial side effects of corticosteroids should be considered in
the decision about such preventive treatment.
Patients Taking Amiodarone
Amiodarone therapy causes thyroid dysfunction in 14
to 18% of the involved patients. Therefore, before initia-
tion of such therapy, patients should have a baseline TSH
measurement, and then they should be monitored at 6-
month intervals during treatment. In patients receiving
amiodarone, either hypothyroidism, which is treated with
levothyroxine replacement, or hyperthyroidism may
develop. Amiodarone-induced hyperthyroidism is of two
types. Type 1 is similar to iodine-induced hyperthyroidism
(jodbasedow phenomenon) and manifests with a low TSH
level, a high free T4 or T3 estimate, and a low radioiodine
uptake. Doppler ultrasonography shows increased vascu-
larity of thyroid tissue, similar to that in Graves’ disease
(13). Because of low radioiodine uptake, 131I treatment
cannot be used, and use of antithyroid drugs has yielded
only varied success. Although mild cases have resolved
even when amiodarone therapy has been continued, con-
sideration of ceasing this drug treatment is recommended.
Restoration of euthyroidism may take months after cessa-
tion of amiodarone therapy. Type 2 amiodarone-induced
hyperthyroidism resembles a destructive thyroiditis.
Laboratory values and radioiodine uptake are similar to
the findings in type 1; however, Doppler ultrasonography
shows decreased vascularity of the thyroid tissue.
Corticosteroid treatment is recommended, and patients
sometimes require surgical removal of the thyroid.
Subclinical Hyperthyroidism
Subclinical hyperthyroidism is characterized by a
serum TSH level <0.1 µIU/mL and normal free T4 and T3
estimates (14-17). The low TSH levels result from either
exogenous TSH suppression or endogenous production of
thyroid hormones that, presumably, is sufficient to keep
free T4 and free T3 levels normal but suppress pituitary
TSH production and secretion. Most studies report a preva-
lence of <2% in the adult or elderly population (17-22).
The clinical significance of subclinical hyperthy-
roidism relates to three risk factors: (1) progression to
overt hyperthyroidism, (2) cardiac effects, and (3) skeletal
effects (17,22-25). In patients who are receiving levothy-
roxine for replacement therapy, the dose should be adjust-
ed so serum TSH values range from 0.3 to 3.0 µIU/mL. An
exception is thyroid hormone replacement treatment after
thyroidectomy for differentiated thyroid cancer, in which
case a mildly to moderately suppressed TSH level is gen-
erally desirable. In addition, some physicians treat hypo-
functional thyroid nodules with levothyroxine in doses
sufficient for minimal suppression of the TSH level.
In patients with subclinical hyperthyroidism attribut-
able to nodular thyroid disease, treatment seems warrant-
ed because of the high rate of conversion to clinical hyper-
thyroidism. Recent studies have suggested that prolonged
subclinical hyperthyroidism may be associated with
decreased bone mineral density (26). Accordingly, inves-
tigators have concluded that subclinical hyperthyroidism
should be considered a risk factor for osteoporosis, partic-
 AACE Thyroid Guidelines, Endocr Pract. 2002;8(No. 6) 463
ularly in postmenopausal women. In men and pre-
menopausal women, bone loss seems to be minimal and of
unknown clinical significance. In elderly patients with
subclinical hyperthyroidism, the relative risk for atrial fi-
brillation increases threefold (22). Other adverse cardiac
effects include impaired left ventricular diastolic filling
and impaired ventricular ejection fraction response to
exercise (24,25).
No consensus exists about the management of sub-
clinical hyperthyroidism. One recent review of the topic
suggested that, in most patients, treatment is unnecessary,
but thyroid function tests should be performed every 6
months (17). AACE recommends that all patients with
subclinical hyperthyroidism should undergo periodic clin-
ical and laboratory assessment to determine individual
therapeutic options.
Clearly, once a suppressed TSH level has been detect-
ed in a specific patient, a reassessment is appropriate to
ensure that the suppressed TSH level is persistent rather
than transient. Therefore, our suggestion is to reassess the
TSH level along with free T4 and T3 estimates in 2 to 4
months. If a sustained TSH suppression (<0.1 µIU/mL) is
established, then management should be based on an indi-
vidual program. For example, patients with symptoms of
hyperthyroidism, atrial fibrillation, or unexplained weight
loss would be appropriate candidates for treatment.
Women with osteopenia or osteoporosis should undergo
assessment for treatment. In patients with multinodular
goiter, treatment should be considered. The treatment
options include antithyroid drugs or radioactive iodine.
Obviously, in elderly women with osteoporosis, the treat-
ment protocol should include calcium, estrogen, bisphos-
phonates, or some combination of these agents (27).
HYPOTHYROIDISM
Hypothyroidism results from undersecretion of thy-
roid hormone from the thyroid gland. In the United States,
the most common cause of primary hypothyroidism is
chronic autoimmune thyroiditis (Hashimoto’s disease).
Other causes are surgical removal of the thyroid gland,
thyroid gland ablation with radioactive iodine, external
irradiation, a biosynthetic defect in iodine organification,
replacement of the thyroid gland by tumor (lymphoma),
and drugs such as lithium or interferon. Secondary causes
of hypothyroidism include pituitary and hypothalamic dis-
ease. Patients should undergo assessment for the cause of
their hypothyroidism.
Clinical Features
The symptoms are generally related to the duration
and severity of hypothyroidism, the rapidity with which
hypothyroidism occurs, and the psychologic characteris-
tics of the patient. The signs and symptoms of hypothy-
roidism can include one or more of the following:
• Fatigue
• Weight gain from fluid retention
• Dry skin and cold intolerance
• Yellow skin
• Coarseness or loss of hair
• Hoarseness
• Goiter
• Reflex delay, relaxation phase
• Ataxia
• Constipation
• Memory and mental impairment
• Decreased concentration
• Depression
• Irregular or heavy menses and infertility
• Myalgias
• Hyperlipidemia
• Bradycardia and hypothermia
• Myxedema fluid infiltration of tissues
Although most physicians can diagnose and treat
hypothyroidism, in certain situations a clinical endocrinol-
ogist experienced in the spectrum of thyroid disease would
be most likely to recognize the more subtle manifestations
of hypothyroidism and most skilled in the physical exam-
ination of the thyroid gland. Consultation with an endocri-
nologist is recommended in the following situations:
• Patients of age 18 years or less
• Patients unresponsive to therapy
• Pregnant patients
• Cardiac patients
• Presence of goiter, nodule, or other structural changes
in the thyroid gland
• Presence of other endocrine disease
Not all patients with chronic thyroiditis have hypothy-
roidism, and if it is present, it may not persist. Rarely,
patients with chronic thyroiditis have a change from a
hypothyroid to a nonsuppressible euthyroid state or even
to a hyperthyroid state because of the development of
stimulating TSH receptor autoantibodies (TSI or TRAb)
of Graves’ disease. If such patients had been receiving
levothyroxine treatment, downward dose adjustments or
even cessation of levothyroxine therapy might be required.
Therefore, adequate follow-up evaluations are imperative.
The patient should be informed that this treatment adjust-
ment may be necessary. When a patient has a goiter, a
complete assessment, including a comprehensive history
and physical examination and appropriate laboratory eval-
uation, should be performed. Patients with chronic thy-
roiditis have a high incidence of other associated autoim-
mune diseases such as vitiligo, rheumatoid arthritis,
Addison’s disease, diabetes mellitus, and pernicious ane-
mia (2,28).
Diagnosis
Laboratory Evaluation
Appropriate laboratory evaluation is critical to estab-
lish the diagnosis and cause of hypothyroidism in the most
464 AACE Thyroid Guidelines, Endocr Pract. 2002;8(No. 6)
cost-effective way. The most valuable test is a sensitive
measurement of TSH level. A TSH assay should always
be used as the primary test to establish the diagnosis of
primary hypothyroidism.
Additional tests may include the following:
• Free T4 estimate
• Thyroid autoantibodies—anti-thyroid peroxidase and
antithyroglobulin autoantibodies
• Thyroid scan, ultrasonography, or both (if necessary to
evaluate suspicious structural thyroid abnormalities)
Differential Diagnosis
A patient with chronic thyroiditis may have an atro-
phic or an enlarged thyroid gland, or it may be of normal
size. Thyroid autoantibodies are positive in 95% of
patients with autoimmune thyroiditis (Hashimoto’s thy-
roiditis), and high titers are of considerable value in mak-
ing this specific diagnosis. Thyroid nodules are not
uncommon with chronic thyroiditis and are associated
with a small risk (5%) of thyroid cancer. Sudden enlarge-
ment of the thyroid gland in a patient with chronic
thyroiditis should raise concern about thyroid lymphoma.
Patients with chronic thyroiditis may have normal
results of thyroid function tests, including the sensitive
TSH. Patients with associated subclinical hypothyroidism
have a high TSH level in conjunction with normal free
thyroid hormone (T4 and T3) estimates. Patients with clin-
ical or overt hypothyroidism exhibit reduced free T4
estimates and increased TSH levels (28,29).
Treatment and Management
Chronic Thyroiditis and Clinical Hypothyroidism
The treatment and management of chronic thyroiditis
and clinical hypothyroidism must be tailored to the indi-
vidual patient. Many clinical endocrinologists treat the
goiter of chronic thyroiditis with levothyroxine, even in
patients with a normal level of TSH, and all physicians
will treat clinical hypothyroidism with levothyroxine
replacement therapy. The management of subclinical
hypothyroidism is addressed in the subsequent section.
AACE advocates the use of a high-quality brand
preparation of levothyroxine. Bioequivalence of levothy-
roxine preparations is based on total T4 measurement and
not TSH levels; therefore, bioequivalence is not the same
as therapeutic equivalence. Furthermore, various brands of
levothyroxine are not compared against a levothyroxine
standard. Preferably, the patient should receive the same
brand of levothyroxine throughout treatment. In general,
desiccated thyroid hormone, combinations of thyroid hor-
mones, or triiodothyronine should not be used as replace-
ment therapy. The mean replacement dosage of levothy-
roxine is 1.6 µg/kg of body weight per day, although the
appropriate dosage may vary among patients. The appro-
priate pace of treatment depends on the duration and
severity of the hypothyroidism and on the presence of
other associated medical disorders. The initial levothyrox-
ine dosage may range from 12.5 µg daily to a full replace-
ment dose based on the age, weight, and cardiac status of
the patient and the severity and duration of the hypothy-
roidism. Importantly, patients should undergo reassess-
ment and therapy should be titrated after an interval of at
least 6 weeks following any change in levothyroxine
brand or dose. The serum TSH level is most important,
and a free T4 estimate may be included in the assessment
as well. Once the TSH level is in the normal range, the fre-
quency of visits can be decreased. Although each patient’s
care must be individualized, a follow-up visit in 6 months
and then annually is a common schedule. During follow-
up assessments, an appropriate interim history should be
recorded, and physical examination should be performed
in conjunction with pertinent laboratory tests. Involving
the patient in the levothyroxine treatment by explaining
the thyroid disease and potential consequences should
result in improved adherence to recommendations.
Thyroid hormone absorption can be affected by mal-
absorptive states and patient age. In addition, commercial-
ly available levothyroxine products may not be bioequiv-
alent. Because levothyroxine has a narrow therapeutic
range, small differences in absorption can result in sub-
clinical or clinical hypothyroidism or hyperthyroidism.
Drug interactions also present a problem. Certain drugs—
such as cholestyramine, ferrous sulfate, sucralfate, calci-
um, and some antacids containing aluminum hydroxide—
interfere with levothyroxine absorption. Other drugs such
as anticonvulsants affect thyroid hormone binding, where-
as others such as rifampin and sertraline hydrochloride
may accelerate levothyroxine metabolism and necessitate
a higher replacement dose. The physician must make the
appropriate adjustments in levothyroxine dosage in the
face of absorption variability and drug interactions.
Inappropriate levothyroxine replacement can result in
increased costs because of the need for additional patient
visits and laboratory tests (28,30-35).
Recent studies have shown a resurgence of interest in
the possible benefits of treatment of hypothyroidism with
combinations of T4 and T3 or with natural thyroid prepa-
rations. The small-scale study that seems to have sparked
this interest treated patients for only 5 weeks, focused on
mood changes, used a T4 plus T3 combination that differs
substantially from that found in natural thyroid products,
may have found benefit in only a subset of patients, and
has not been replicated (36,37). Insufficient evidence is
available to know which patients with hypothyroidism, if
any, would be better treated with a combination of T4 plus
T3 rather than with T4 alone.
Subclinical Hypothyroidism
Subclinical hypothyroidism refers to mildly increased
serum TSH levels in the setting of normal free T4 and T3
estimates. Although subclinical hypothyroidism may rep-
resent “early” thyroid failure, it may occur in the presence
or absence of symptoms. It is a common disorder, the
prevalence ranging from 1 to 10% of the adult population
with increasing frequency in women, in patients with
advanced age, and in those with greater dietary iodine
intake. Usually, subclinical hypothyroidism is asympto-
 AACE Thyroid Guidelines, Endocr Pract. 2002;8(No. 6) 465
matic and is discovered on routine, screening TSH deter-
mination. The most common cause of subclinical hypothy-
roidism is autoimmune thyroiditis (Hashimoto’s disease).
Progression to overt hypothyroidism is reported to vary
from 3 to 20%, the risks being greater in those patients
with goiter or thyroid antibodies (or both) (16,18).
Although subclinical hypothyroidism is often asymp-
tomatic, potential risks associated with the condition
include progression to overt hypothyroidism, cardiovascu-
lar effects, hyperlipidemia, and neuropsychiatric effects
(16,19). Recent studies have suggested that treatment of
subclinical hypothyroidism will reduce cardiovascular risk
factors, improve the lipid profile, and minimize neurobe-
havioral abnormalities (19,20). Some of these data, how-
ever, were derived from studies that included patients with
TSH levels well above 10 µIU/mL; for patients with mild-
ly increased TSH levels (5 to 10 µIU/mL), the data are
controversial.
Treatment of subclinical hypothyroidism remains
controversial, and recent arguments for and against treat-
ment have been proposed (19,21). We believe that treat-
ment is indicated in patients with TSH levels >10 µIU/mL
or in patients with TSH levels between 5 and 10 µIU/mL
in conjunction with goiter or positive anti-thyroid peroxi-
dase antibodies (or both). These patients have the highest
rates of progression to overt hypothyroidism. An initial
dosage of levothyroxine of 25 to 50 µg/day can be used,
the serum TSH level should be measured in 6 to 8 weeks,
and the levothyroxine dose should be adjusted as neces-
sary. The target TSH level should be between 0.3 and 3.0
µIU/mL. Once a stable TSH level is achieved, annual
examination is appropriate.
Hypothyroidism During Pregnancy
Untreated overt hypothyroidism during pregnancy
may increase the incidence of maternal hypertension,
preeclampsia, anemia, postpartum hemorrhage, cardiac
ventricular dysfunction, spontaneous abortion, fetal death
or stillbirth, low birth weight, and, possibly, abnormal
brain development (38). Evidence from a population-
based study suggests that even mild, asymptomatic,
untreated maternal hypothyroidism during pregnancy may
have an adverse effect on cognitive function of the off-
spring and that this outcome can be prevented by thyroid
hormone replacement therapy (39). Mildly increased
serum TSH levels during pregnancy might also increase
the risk of fetal death, but whether treatment prevents this
complication is not yet known. In most of these women,
thyroid antibodies develop—a finding that seems to be a
risk factor for spontaneous abortion independent of thy-
roid hormone and TSH levels (38,40). Because levothy-
roxine therapy is safe during pregnancy, thyroid hormone
replacement treatment seems advisable for all pregnant
women with hypothyroidism, even if it is mild. As a fur-
ther recommendation, TSH measurement should be rou-
tine before pregnancy or during first trimester screening
for thyroid dysfunction.
When a woman with hypothyroidism or underlying
chronic thyroiditis becomes pregnant, the thyroid function
may change—it can improve in some mild cases or deteri-
orate in others. In general, the dosage of thyroid hormone
should be increased in patients with moderate to severe
hypothyroidism. These patients should undergo assess-
ment of their serum TSH level every 6 weeks during preg-
nancy to ensure that the requirement for levothyroxine has
not changed (41-43).
Hypothyroidism and Concurrent Conditions
Diabetes Mellitus
In approximately 10% of patients with type 1 diabetes
mellitus, chronic thyroiditis will develop during their life-
time, which may include the insidious onset of subclinical
hypothyroidism. Of importance, patients with diabetes
should be examined for the development of a goiter.
Sensitive TSH measurements should be obtained at regu-
lar intervals in patients with diabetes, especially if a goiter
develops or if evidence is found of other autoimmune dis-
orders. In addition, postpartum thyroiditis will develop in
up to 25% of women with type 1 diabetes (44,45).
Infertility
Some patients with infertility and menstrual irregular-
ities have underlying chronic thyroiditis in conjunction
with subclinical or clinical hypothyroidism. Typically,
these patients seek medical attention because of infertility
or a previous miscarriage, rather than hypothyroidism.
Chronic thyroiditis can be identified by a careful, compre-
hensive history, physical examination, and appropriate
laboratory evaluation. In some patients with high TSH
levels, levothyroxine replacement therapy may normalize
the menstrual cycle and restore normal fertility (2,28,46).
Depression
The diagnosis of subclinical or clinical hypothy-
roidism must be considered in every patient with depres-
sion. In fact, a small proportion of all patients with
depression have primary hypothyroidism—either overt or
subclinical. Moreover, all patients receiving lithium
therapy require periodic thyroid evaluation because
lithium may induce goiter and hypothyroidism.
The diagnosis of chronic thyroiditis or subclinical or
clinical hypothyroidism is based on a high serum TSH
level and positive thyroid autoantibodies. Appropriate
levothyroxine replacement therapy should be instituted.
Occasionally in psychiatric practice, some patients who
have depression are treated not only with antidepressants
but also with thyroid hormone replacement, even though
they have normal thyroid function. No firm evidence has
shown that thyroid hormone treatment alone does any-
thing to alleviate depression in such patients (28,33).
Euthyroid Sick Syndrome
The evaluation of thyroid function in chronically ill
patients may be confusing. Many medications, such as
466 AACE Thyroid Guidelines, Endocr Pract. 2002;8(No. 6)
corticosteroids and dopamine, may interfere with the
results of thyroid function tests. In addition, when a patient
is ill or starving, the body tends to compensate by decreas-
ing metabolic rates, which may result in a low free T4 or
T3 estimate and a normal or low TSH level. If the TSH
value is less than 10 µIU/mL, treatment should ideally be
deferred until the patient’s medical condition has resolved.
Assessment of the patient by a clinical endocrinologist is
appropriate before initiation of levothyroxine treatment.
CONCLUSION
These guidelines established by AACE present sever-
al approaches to the assessment and treatment of patients
with hyperthyroidism and hypothyroidism. They highlight
the complexity of thyroid diseases and describe diagnostic
and therapeutic strategies in various settings. These guide-
lines are not intended to be a comprehensive outline of
therapeutic options.
Subclinical thyroid disease often remains undiag-
nosed. Through sound judgment, timely intervention, ini-
tiation of appropriate treatment, and patient involvement,
an optimal level of care is attainable.
REFERENCES
1. Thyroid Guidelines Committee. AACE clinical practice
guidelines for the evaluation and treatment of hyperthy-
roidism and hypothyroidism. Endocr Pract. 1995;1:54-62.
2. Larsen PR, Davies TF, Hay ID. The thyroid gland. In:
Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds.
Williams Textbook of Endocrinology. 9th ed. Philadelphia:
WB Saunders Co, 1998: 389-515.
3. Franklyn JA. The management of hyperthyroidism [erra-
tum in N Engl J Med. 1994;331:559]. N Engl J Med. 1994;
330:1731-1738.
4. Braverman LE, Utiger RD. Introduction to thyrotoxico-
sis. In: Braverman LE, Utiger RD, eds. Werner and
Ingbar’s The Thyroid: A Fundamental and Clinical Text.
6th ed. Philadelphia: JB Lippincott Co, 1991: 645-647.
5. O’Donnell AL, Spaudling SW. Hyperthyroidism: sys-
temic effects and differential diagnosis. In: Falk SA, ed.
Thyroid Disease: Endocrinology, Surgery, Nuclear
Medicine, and Radiotherapy. 2nd ed. Philadelphia:
Lippincott-Raven Publishers, 1997: 241-252.
6. Cooper DS. Treatment of thyrotoxicosis. In: Braverman
LE, Utiger RD, eds. Werner and Ingbar’s The Thyroid: A
Fundamental and Clinical Text. 6th ed. Philadelphia: JB
Lippincott Co, 1991: 887-916.
7. Farwell AP, Braverman LE. Thyroid and antithyroid
drugs. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon
RW, Gilman AG, eds. Goodman & Gilman’s The
Pharmacological Basis of Therapeutics. 9th ed. New York:
McGraw-Hill, 1996: 1383-1409.
8. Tallstedt L, Lundell G, Torring O, et al (Thyroid Study
Group). Occurrence of ophthalmopathy after treatment for
Graves’ hyperthyroidism. N Engl J Med. 1992;326:1733-
1738.
9. Bartalena L, Marcocci C, Bogazzi F, et al. Relation
between therapy for hyperthyroidism and the course of
Graves’ ophthalmopathy. N Engl J Med. 1998;338:73-78.
10. Gorman CA. Therapeutic controversies: radioiodine ther-
apy does not aggravate Graves’ ophthalmopathy. J Clin
Endocrinol Metab. 1995;80:340-342.
11. Gorman CA, Offord KP. Therapy for hyperthyroidism
and Graves’ ophthalmopathy [letter]. N Engl J Med. 1998;
338:1546-1547.
12. Bartalena L, Marcocci C, Bogazzi F, Panicucci M,
Lepri A, Pinchera A. Use of corticosteroids to prevent
progression of Graves’ ophthalmopathy after radioiodine
therapy for hyperthyroidism. N Engl J Med. 1989;321:
1349-1352.
13. Bogazzi F, Bartalena L, Martino E. Color flow Doppler
sonography of the thyroid. In: Baskin HJ, ed. Thyroid
Ultrasound and Ultrasound-Guided FNA Biopsy. Boston:
Kluwer Academic Publishers, 2000: 227-229.
14. Wiersinga WM. Subclinical hypothyroidism and hyper-
thyroidism. I. Prevalence and clinical relevance. Neth J
Med. 1995;46:197-204.
15. Subclinical hyperthyroidism: position statement from the
American Association of Clinical Endocrinologists.
Endocr Pract. 1999;5:220-221.
16. Cooper DS. Clinical practice: subclinical hypothyroidism.
N Engl J Med. 2001;345:260-265.
17. Toft AD. Clinical practice: subclinical hyperthyroidism. N
Engl J Med. 2001;345:512-516.
18. Tunbridge WM, Evered DC, Hall R, et al. The spectrum
of thyroid disease in a community: the Whickham survey.
Clin Endocrinol (Oxf). 1977;7:481-493.
19. McDermott MT, Ridgway EC. Subclinical hypothy-
roidism is mild thyroid failure and should be treated. J Clin
Endocrinol Metab. 2001;86:4585-4590.
20. Danese MD, Ladenson PW, Meinert CL, Powe NR.
Clinical review 115: effect of thyroxine therapy on serum
lipoproteins in patients with mild thyroid failure; a quanti-
tative review of the literature. J Clin Endocrinol Metab.
2000;85:2993-3001.
21. Chu JW, Crapo LM. The treatment of subclinical
hypothyroidism is seldom necessary. J Clin Endocrinol
Metab. 2001;86:4591-4599.
22. Helfand M, Redfern CC. Clinical guideline, part 2:
screening for thyroid disease; an update. American College
of Physicians [erratum in Ann Intern Med. 1999;130:246].
Ann Intern Med. 1998;129:144-158.
23. Sawin CT, Geller A, Wolf PA, et al. Low serum thy-
rotropin concentration as a risk factor for atrial fibrillation
in older patients. N Engl J Med. 1994;331:1249-1252.
24. Biondi B, Fazio S, Cuocolo A, et al. Impaired cardiac
reserve and exercise capacity in patients receiving long-
term thyrotropin suppressive therapy with levothyroxine. J
Clin Endocrinol Metab. 1996;81:4224-4228.
25. Biondi B, Palmieri EA, Fazio S, et al. Endogenous sub-
clinical hyperthyroidism affects quality of life and cardiac
morphology and function in young and middle-aged
patients. J Clin Endocrinol Metab. 2000;85:4701-4705.
26. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L,
Siersbaek-Nielsen K. Normalization of serum thy-
rotrophin by means of radioiodine treatment in subclinical
hyperthyroidism: effect on bone loss in postmenopausal
women. Clin Endocrinol (Oxf). 1998;48:285-290.
27. Gharib H, Mazzaferri EL. Thyroxine suppressive thera-
py in patients with nodular thyroid disease. Ann Intern
Med. 1998;128:386-394.
28. Utiger RD. Hypothyroidism. In: DeGroot LJ, ed.
Endocrinology. Vol 1. 2nd ed. Philadelphia: WB Saunders
Co, 1989: 702-721.
29. Becker DV, Bigos ST, Gaitan E, et al. Optimal use of
blood tests for assessment of thyroid function. Thyroid.
1993;3:353-354.
30. Mandel SJ, Brent GA, Larsen PR. Levothyroxine thera-
py in patients with thyroid disease. Ann Intern Med. 1993;
119:492-502.
 AACE Thyroid Guidelines, Endocr Pract. 2002;8(No. 6) 467
31. Surks MI. Treatment of hypothyroidism. In: Braverman
LE, Utiger RD, eds. Werner and Ingbar’s The Thyroid: A
Fundamental and Clinical Text. 6th ed. Philadelphia: JB
Lippincott Co, 1991: 1099-1103.
32. Griffin JE. Hypothyroidism in the elderly. Am J Med Sci.
1990;299:334-345.
33. Roti E, Braverman LE. Thyroid hormone therapy: when
to use it, when to avoid it. Drug Therapy. 1994;24:28-35.
34. Hays MT, Nielsen KR. Human thyroxine absorption: age
effects and methodological analyses. Thyroid. 1994;4:55-
64.
35. McEvoy GK. AHFS Drug Information 94. Bethesda, MD:
American Hospital Formulary Service, 1994: 2101.
36. Bunevicius R, Kazanavicius G, Zalinkevicius R, Prange
AJ Jr. Effects of thyroxine as compared with thyroxine
plus triiodothyronine in patients with hypothyroidism. N
Engl J Med. 1999;340:424-429.
37. Bunevicius R, Prange AJ. Mental improvement after
replacement therapy with thyroxine plus triiodothyronine:
relationship to cause of hypothyroidism. Int J Neuropsy-
chopharmacol. 2000;3:167-174.
38. Kaplan MM, Meier DA. Thyroid diseases in pregnancy.
In: Gleicher N, ed. Principles and Practice of Medical
Therapy in Pregnancy. 3rd ed. Stanford: Appleton and
Lange, 1998: 432-448.
39. Haddow JE, Palomaki GE, Allan WC, et al. Maternal
thyroid deficiency during pregnancy and subsequent neu-
ropsychological development of the child. N Engl J Med.
1999;341:549-555.
40. Allan WC, Haddow JE, Palomaki GE, et al. Maternal
thyroid deficiency and pregnancy complications: implica-
tions for population screening. J Med Screen. 2000;7:127-
130.
41. Kaplan MM. Monitoring thyroxine treatment during preg-
nancy. Thyroid. 1992;2:147-152.
42. Mandel SJ, Larsen PR, Seely EW, Brent GA. Increased
need for thyroxine during pregnancy in women with pri-
mary hypothyroidism. N Engl J Med. 1990;323:91-96.
43. Tamaki H, Amino N, Takeoka K, Mitsuda N, Miyai K,
Tanizawa O. Thyroxine requirement during pregnancy for
replacement therapy of hypothyroidism. Obstet Gynecol.
1990;76:230-233.
44. Stagnaro-Green A. Postpartum thyroiditis: prevalence,
etiology, and clinical implications. Thyroid Today. 1993;
16:1-11.
45. Alvarez-Marfany M, Roman SH, Drexler AJ,
Robertson C, Stagnaro-Green A. Long-term prospective
study of postpartum thyroid dysfunction in women with
insulin dependent diabetes mellitus. J Clin Endocrinol
Metab. 1994;79:10-16.
46. Longecope C. The male and female reproductive systems
in hypothyroidism. In: Braverman LE, Utiger RD, eds.
Werner and Ingbar’s The Thyroid: A Fundamental and
Clinical Text. 6th ed. Philadelphia: JB Lippincott Co,
1991: 1052-1063.
468 AACE Thyroid Guidelines, Endocr Pract. 2002;8(No. 6)

APPENDIX A

Sample Consent Form for Treatment With Radioactive Iodine

Patient Age Date

I hereby request and authorize Dr. or a designated assistant to administer

radioactive iodine to (patient).

The effect and nature of this treatment and any potential adverse reactions have been explained to me. I understand that
this treatment may eliminate part or all of my thyroid gland and that, as a consequence, I may require lifetime treatment
with thyroid medication. Also, in a few instances, this treatment may not be entirely effective, and a second dose of
radioactive iodine would then be necessary.

I voluntarily accept the risks involved in this treatment.

I have been informed that examinations by Dr. will be necessary every

4 weeks for at least 3 months after the treatment, or as otherwise recommended. Subsequent periodic follow-up may be
necessary.

Signature of patient

Signature of parent or guardian

Signature of witness
 AACE Thyroid Guidelines, Endocr Pract. 2002;8(No. 6) 469

APPENDIX B

Instructions for Patient After Radioactive Iodine Treatment

1. Do not kiss, exchange saliva, or share food or eating utensils for 5 days. Your dishes should be washed in a
dishwasher, if one is available.
2. Avoid close contact with infants, young children (under 8 years), and pregnant women for 5 days. (You can
be in the same room with them.)
3. If you have an infant, no breast-feeding is allowed.
4. Flush the toilet twice after urinating, and wash your hands thoroughly.
5. If a sore throat or neck pain develops, take acetaminophen or aspirin.
6. If you note increased nervousness, tremulousness, or palpitations, call a physician.